These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3886402)

  • 1. Controlled clinical trial of cadralazine as a second-step drug in the treatment of hypertension.
    Catalano M; Parini J; Romano M; Libretti A
    Eur J Clin Pharmacol; 1985; 28(2):135-8. PubMed ID: 3886402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cadralazine and chlorthalidone as a second-step drug with atenolol in hypertensive patients: differences in blood pressure control during exercise.
    Costa FV; Borghi C; Mussi A; Ambrosioni E
    Eur J Clin Pharmacol; 1986; 30(2):145-50. PubMed ID: 3709638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
    Salvadeo A; Villa G; Segagni S; Piazza V; Picardi L; Romano M; Parini J
    Arzneimittelforschung; 1985; 35(3):623-5. PubMed ID: 2859865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison.
    Curry RC; Schwartz KM; Urban PL
    South Med J; 1988 Nov; 81(11):1401-6, 1411. PubMed ID: 3055324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of cadralazine or chlorthalidone in verapamil-treated elderly hypertensives.
    Antonicelli R; Savonitto S; Tomassini PF; Gambini C; Sardina M; Paciaroni E
    Int J Clin Pharmacol Ther; 1994 Apr; 32(4):198-203. PubMed ID: 8032580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cadralazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
    McTavish D; Young RA; Clissold SP
    Drugs; 1990 Oct; 40(4):543-60. PubMed ID: 2083513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
    Buoninconti R; Motolese M
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
    Holzgreve H; Nakov R; Beck K; Janka HU
    Am J Hypertens; 2003 May; 16(5 Pt 1):381-6. PubMed ID: 12745200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute systemic and renal haemodynamic effects and long-term antihypertensive action of cadralazine in patients pretreated with beta-blockers and diuretics.
    Persson B; Granerus G; Wysocki M; Hedner T; Andersson OK
    Eur J Clin Pharmacol; 1987; 31(5):513-8. PubMed ID: 2881788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of a fixed-dosage combination of atenolol and chlorthalidone (Tenoretic) in hypertensive Nigerians.
    Salako LA; Falase AO; Aderounmu AF; Walker O
    Afr J Med Med Sci; 1990 Mar; 19(1):57-61. PubMed ID: 2109522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-strength atenolol-chlorthalidone combination (tenoretic mite) in the treatment of elderly hypertensive patients.
    Fogari R; Zoppi A
    Int J Clin Pharmacol Ther Toxicol; 1984 Jul; 22(7):386-93. PubMed ID: 6469428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose atenolol-chlorthalidone combination for treatment of mild hypertension.
    Leonetti G; Pasotti C; Capra A
    Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):43-7. PubMed ID: 3514487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic treatment with tibalosine in essential hypertension.
    Staessen J; Fagard R; Fiocchi R; Lijnen P; M'Buyamba-Kabangu JR; Amery A
    Arch Int Pharmacodyn Ther; 1986 Jan; 279(1):162-76. PubMed ID: 3516092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atenolol and chlorthalidone in combination for hypertension.
    Bateman DN; Dean CR; Mucklow JC; Bulpitt CJ; Dollery CT
    Br J Clin Pharmacol; 1979 Apr; 7(4):357-63. PubMed ID: 375958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atenolol and chlorthalidone in combination in the management of older hypertensive patients: a randomized clinical trial.
    Backhouse CI; Hosie J; Tweed JA; Edwards KG
    Curr Med Res Opin; 1985; 9(6):378-83. PubMed ID: 3886301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: a multicenter, randomized, controlled study.
    Pareek A; Karnik N; Salagre SB; Zawar SD; Joglekar VK; Chandurkar N; Naik GS
    Curr Med Res Opin; 2008 Jun; 24(6):1771-9. PubMed ID: 18479589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atenolol and chlorthalidone on blood pressure, heart rate, and plasma renin activity in hypertension.
    Teeuw AH; Leenen FH; Geyskes GG; Boer P
    Clin Pharmacol Ther; 1979 Mar; 25(3):294-302. PubMed ID: 367678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the antihypertensive effect of atenolol in fixed or free combination with chlorthalidone.
    Nissinen A; Tuomilehto J
    Pharmatherapeutica; 1980; 2(7):462-8. PubMed ID: 7010382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the antihypertensive activity of cadralazine (ISF 2469) and dihydralazine during chronic treatment.
    Strocchi E; Costa FV; Caldari R; Malini PL; Marata AM; Parini J; Ambrosioni E
    Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):519-23. PubMed ID: 6642790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive effect of atenolol alone or combined with chlorthalidone in patients with essential hypertension.
    Velasco M; Guevara J; Morillo J; Ramírez A; Urbina-Quintana A; Hernández-Pieretti O
    Br J Clin Pharmacol; 1980 May; 9(5):499-504. PubMed ID: 6994790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.